Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET/MRI scan could spot elusive brain tumors in Cushing's patients

NCT ID NCT03346954

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special scan called [11C]-Methionine PET/MRI can better locate tiny pituitary tumors that cause Cushing's disease. Standard MRI often misses these tumors, leading to risky exploratory surgery. The study involved 33 adults with confirmed Cushing's disease who received the new scan before surgery. If successful, this approach could reduce the need for invasive catheter tests and improve surgical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[11C]-Methionine (a radioactive tracer used in PET imaging)
What this could lead to
If this scan works well, it could help doctors find hidden pituitary tumors more accurately, reducing the need for invasive catheter tests and improving surgical success.
What could go wrong
This was a small, completed study with only 33 people, so results may not apply to everyone. The scan may still miss some tumors or give false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Dec 2017

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years old or over * Patient with a diagnosed Cushing's disease according to the French "protocole national de diagnostic et de soins (PNDS)" * Patient who underwent a MRI pituitary for diagnostic purposes * Patient who have undergone catheterization of the lower petrosal sinuses (if MRI does not detect pituitary adenoma) and have a result in favor of a central secretion of ACTH * Patient having an indication of surgical excision of the adenoma * Patient with a micro-adenoma (less than 1 cm in diameter) if the tumor is visualized on MRI * Patient for which informed and written consent to participate has been obtained. Exclusion Criteria: * \- Patient participating in another study * Patient with a pituitary macro-adenoma with visual impairment * Patient with ACTH-dependent Cushing's syndrome secondary to ectopic ACTH secretion * Patient with recurrence and / or history of pituitary adenoma excision * Patient with a contraindication to pituitary surgery or general anesthesia * Pregnant woman, breastfeeding or old enough to have children but without effective recognized contraception * Contra-indication to the realization of an MRI: permanently fixed metal parts (pacemaker, cerebral clip, cephalic end piercing, cochlear implant, pin or screw for recent bone fracture, dental equipment, metal splinters), claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cushing's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome allergic disease Cushing disease due to pituitary adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing's disease

Contacts and locations

Locations

  • Service de Médecine Nucléaire - Hospices Civils de Lyon

    Bron, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.